Can a smaller dose of sugammadex rescue patients when standard reversal fails?
NCT ID NCT05661409
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested five different low doses of sugammadex (a drug that reverses muscle relaxants) in 46 adults who still had muscle weakness after the standard reversal drug neostigmine. The goal was to see how quickly each dose restored normal muscle function. If a lower dose works, it could give doctors more options and reduce side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sugammadex
- What this could lead to
- If successful, this could help anesthesiologists use lower, more precise doses of sugammadex to quickly reverse muscle relaxation when the usual drug doesn't work well enough.
- What could go wrong
- This is a small, early-phase trial with only 46 participants, so results may not apply to all patients. Lower doses might not work as well as the standard dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMUSCULAR BLOCKADE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Grady Memorial Hospital
Atlanta, Georgia, 30303, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple skin scrub sharpen surgical monitoring?
- Can a new drug improve muscle relaxation during surgery?
- Do two muscle monitors tell the same story?
- Which monitor best tracks deep muscle paralysis during keyhole surgery?
- Which monitor best measures muscle relaxation on the operating table?
- Spine surgery study tests best way to use muscle relaxants for safer monitoring